143 related articles for article (PubMed ID: 24225910)
1. Durable recovery of the macular architecture and functionality of a diagnosed age-related macular degeneration 1 year after a single intravitreal injection of dobesilate.
Cuevas P; Outeiriño LA; Azanza C; Giménez-Gallego G
BMJ Case Rep; 2013 Nov; 2013():. PubMed ID: 24225910
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Stargardt disease with dobesilate.
Cuevas P; Outeiriño LA; Angulo J; Giménez-Gallego G
BMJ Case Rep; 2012 Oct; 2012():. PubMed ID: 23076703
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal dobesilate in the treatment of choroidal neovascularisation associated with age-related macular degeneration: report of two cases.
Cuevas P; Outeiriño L; Azanza C; Giménez-Gallego G
BMJ Case Rep; 2012 Sep; 2012():. PubMed ID: 22948997
[TBL] [Abstract][Full Text] [Related]
4. Treatment of dry age-related macular degeneration with dobesilate.
Cuevas P; Outeiriño LA; Angulo J; Giménez-Gallego G
BMJ Case Rep; 2012 Jun; 2012():. PubMed ID: 22729337
[TBL] [Abstract][Full Text] [Related]
5. Short-term efficacy of intravitreal dobesilate in central serous chorioretinopathy.
Cuevas P; Outeiriño LA; Azanza C; Angulo J; Giménez-Gallego G
Eur J Med Res; 2012 Jul; 17(1):22. PubMed ID: 22788836
[TBL] [Abstract][Full Text] [Related]
6. Focal macular electroretinograms after intravitreal injections of bevacizumab for age-related macular degeneration.
Iwata E; Ueno S; Ishikawa K; Ito Y; Uetani R; Piao CH; Kondo M; Terasaki H
Invest Ophthalmol Vis Sci; 2012 Jun; 53(7):4185-90. PubMed ID: 22618591
[TBL] [Abstract][Full Text] [Related]
7. Chronic cystoid macular oedema treated with intravitreal dobesilate.
Cuevas P; Outeiriño LA; Angulo J; Giménez-Gallego G
BMJ Case Rep; 2012 Jul; 2012():. PubMed ID: 22778475
[TBL] [Abstract][Full Text] [Related]
8. Full thickness macular hole case after intravitreal aflibercept treatment.
Oshima Y; Apte RS; Nakao S; Yoshida S; Ishibashi T
BMC Ophthalmol; 2015 Mar; 15():30. PubMed ID: 25881212
[TBL] [Abstract][Full Text] [Related]
9. Correlation between macular structure and function in patients with age-related macular degeneration treated with intravitreal ranibizumab: 12-month-results.
Nishimura T; Machida S
Jpn J Ophthalmol; 2019 Jan; 63(1):90-99. PubMed ID: 30470956
[TBL] [Abstract][Full Text] [Related]
10. Long-term changes in retinal layers in patients undergoing intravitreal ranibizumab for neovascular age-related macular degeneration : Retinal layers after anti-VEGF therapy.
Inan ÜÜ; Baysal Z; Inan S
Int Ophthalmol; 2019 Dec; 39(12):2721-2730. PubMed ID: 31069616
[TBL] [Abstract][Full Text] [Related]
11. Combined treatment of photodynamic therapy and bevacizumab for choroidal neovascularization secondary to age-related macular degeneration.
Kim HW; Kim JL; Lee MH; Yoo HG; Chung IY; Lee JE
Korean J Ophthalmol; 2011 Aug; 25(4):231-7. PubMed ID: 21860568
[TBL] [Abstract][Full Text] [Related]
12. EFFICACY OF ADJUVANT TOPICAL DORZOLAMIDE-TIMOLOL IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION REFRACTORY TO ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.
Lee JH; Lee SC; Byeon SH; Koh HJ; Kim SS; Lee CS
Retina; 2019 Oct; 39(10):1953-1958. PubMed ID: 30161096
[TBL] [Abstract][Full Text] [Related]
13. Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.
Veloso CE; Kanadani TM; Pereira FB; Nehemy MB
Ophthalmology; 2015 Aug; 122(8):1569-72. PubMed ID: 26038338
[TBL] [Abstract][Full Text] [Related]
14. Three-month outcome of ziv-aflibercept for exudative age-related macular degeneration.
Mansour AM; Chhablani J; Antonios RS; Yogi R; Younis MH; Dakroub R; Chahine H
Br J Ophthalmol; 2016 Dec; 100(12):1629-1633. PubMed ID: 27030277
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of treat-and-extend regimen with aflibercept for pachychoroid neovasculopathy and Type 1 neovascular age-related macular degeneration.
Matsumoto H; Hiroe T; Morimoto M; Mimura K; Ito A; Akiyama H
Jpn J Ophthalmol; 2018 Mar; 62(2):144-150. PubMed ID: 29411171
[TBL] [Abstract][Full Text] [Related]
16. Two-year functional and anatomical results after converting treatment resistant eyes with exudative age-related macular degeneration to aflibercept in accordance with a treat and extend protocol.
Jørstad ØK; Faber RT; Moe MC
Acta Ophthalmol; 2017 Aug; 95(5):460-463. PubMed ID: 28556485
[TBL] [Abstract][Full Text] [Related]
17. Duration of action of intravitreal ranibizumab and bevacizumab in exudative AMD eyes based on macular volume measurements.
Shah AR; Del Priore LV
Br J Ophthalmol; 2009 Aug; 93(8):1027-32. PubMed ID: 19429594
[TBL] [Abstract][Full Text] [Related]
18. Impact of vitreomacular adhesion on ranibizumab mono- and combination therapy for neovascular age-related macular degeneration.
Waldstein SM; Ritter M; Simader C; Mayr-Sponer U; Kundi M; Schmidt-Erfurth U
Am J Ophthalmol; 2014 Aug; 158(2):328-336.e1. PubMed ID: 24794282
[TBL] [Abstract][Full Text] [Related]
19. Aflibercept therapy in eyes with neovascular age-related macular degeneration and its effect on choroidal thickness.
Sariyeva Ismayılov A; Esen E; Sızmaz S; Demircan AN
Clin Exp Optom; 2019 Nov; 102(6):617-620. PubMed ID: 30793798
[TBL] [Abstract][Full Text] [Related]
20. [Managment of subretinal heamorrhages within the macular area using intravitreal injections of recombined tissue plasminogen activator, sulphur hexafluoride and ranihizumab--preliminary report].
Miniewicz J; Kubicka-Trząska A; Karska-Basta I; Romanowska-Dixon B
Klin Oczna; 2015; 117(3):165-8. PubMed ID: 26999939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
